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Abstract 
Background: Empiric antibiotic therapy is routinely prescribed in patients with acute COPD exacerbations (AECOPD) 
requiring ventilatory support on the basis of studies including patients conventionally ventilated. Whether this prac‑
tice remains valid to current management with first‑line non‑invasive ventilation (NIV) is unclear.
Methods: In a cohort of ICU patients admitted between 2000 and 2012 for AECOPD, we analyzed the trends in 
empiric antibiotic therapy and in primary ventilatory support strategy, and their respective impact on patients’ 
outcome.
Results: 440 patients admitted for 552 episodes were included; primary NIV use increased from 29 to 96.7 % 
(p < 0.001), whereas NIV failure rate decreased significantly (p = 0.004). In parallel, ventilator‑associated pneumonia 
(VAP) rate, VAP density and empiric antibiotic therapy use decreased (p = 0.037, p = 0.002, and p < 0.001, respec‑
tively). These figures were associated with a trend toward lower ICU mortality rate (p = 0.058). Logistic regression 
showed that primary NIV use per se was protective against fatal outcome [odds ratios (OR) = 0.08, 95 %CI 0.03–0.22; 
p < 0.001], whereas NIV failure, VAP occurrence, and cardiovascular comorbidities were associated with increased ICU 
mortality [OR = 17.6 (95 %CI 5.29–58.93), 11.5 (95 %CI 5.17–25.45), and 3 (95 %CI 1.37–6.63), respectively]. Empiric 
antibiotic therapy was associated with decreased VAP rate (log rank; p < 0.001), but had no effect on mortality (log 
rank; p = 0.793).
Conclusions: The sustained increase in NIV use allowed a decrease in empiric antibiotic prescriptions in AECOPD 
requiring ventilatory support. Primary NIV use and its success, but not empiric antibiotic therapy, were associated with 
a favorable impact on patients’ outcome.
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Background
Chronic obstructive pulmonary disease (COPD) has 
become the third leading cause of mortality worldwide 
[1–3]. Its natural history is marked by the occurrence 
of episodes of acute exacerbations (AECOPD) contrib-
uting to a progressive decline in respiratory function 
and impaired quality of life [4–8]. Exacerbations are 
also an important source of care expenditures, as they 
are responsible for more than 700,000 hospitaliza-
tions annually in the USA and a total cost of $36 billion 
[9–12]. Intensive care unit (ICU) plays a pivotal role in 
the management of severe hypercapnic COPD exacer-
bation, where treatment relies mainly on ventilatory 
support, in addition to commonly administered medica-
tions and control of exacerbation triggers [13, 14].
Respiratory infections are the most frequent causes 
of COPD exacerbations, accounting for 50–80  % of all 
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exacerbations, and antibiotics are commonly adminis-
tered [15–19] and still recommended especially by the 
last GOLD guidelines, in the setting of severe COPD 
exacerbations [4]. This practice is based on microbiologi-
cal studies showing a higher prevalence of bacteria in the 
airways of patients during exacerbation, in comparison 
with stable COPD and healthy subjects [20–22]. How-
ever, the clinical relevance of bacterial presence in the 
airways has been questioned, and the lack of sensitive 
and specific diagnosis tools adds difficulties in determin-
ing the precise proportion of bacterial infections among 
other causes of exacerbation to better guide antibiotic 
therapy [23–27]. Moreover, approximately one-third of 
severe exacerbation episodes remain without identified 
cause [22, 28–32].
A randomized controlled trial conducted between 1996 
and 1999 in our ICU is frequently quoted as the main 
source of evidence supporting empiric antibiotic therapy 
in patients with AECOPD requiring ventilatory support 
[33]. This trial showed that the rate of in-hospital mor-
tality in the treated group was five times lower than that 
recorded in the placebo group. The results also suggested 
that the beneficial effects of antibiotic administration 
might have resulted from its selective digestive decon-
tamination-like effect, with a substantial reduction in the 
ventilator-associated pneumonia (VAP) rate. At the time 
that the study was conducted, non-invasive ventilation 
(NIV) was an emerging technique and failures requiring 
intubation were frequent (up to 80  %). Accordingly, the 
majority of these patients ultimately received conven-
tional mechanical ventilation as the primary method of 
ventilation. NIV has since gained ground as the first-line 
method of ventilation in hypercapnic COPD exacerba-
tion [34–36] and has been associated with lower com-
plications and improved outcome and lower costs of 
care [37, 38]. NIV use has progressively increased in our 
department with a better mastering of the technique by 
the health-care team; in this context of changing prac-
tices, the beneficial effect of routine empiric antibiotic 
therapy should be reconsidered.
In this study, we describe the changing pattern of pri-
mary ventilation method in our ICU and investigate 
whether the increased use of NIV would impact the 
empirical antibiotic prescription in the exacerbation 
of COPD, a practice that is common and still recom-
mended. The respective impact of the ventilation method 
and empiric antibiotic therapy on patient-centered out-
comes is also assessed.
Methods
This is an observational cohort study, conducted in the 
ten-bed medical ICU of the teaching university hospital 
Fattouma Bourguiba of Monastir (802 beds) during the 
period between 1 January 2000 and 31 December 2012. 
Given the observational design of the study, the institu-
tional review board of our hospital waived the need of a 
formal study approval.
Inclusion criteria
We included consecutive patients admitted to the ICU 
for AECOPD during the study period and requiring ven-
tilatory support.
Non‑inclusion criteria
We did not include in the present study patients with 
acute respiratory failure on other chronic lung disease 
than COPD (asthma, pulmonary fibrosis, etc.), COPD 
patients with an obvious cause of acute respiratory fail-
ure (pneumonia, pneumothorax, pulmonary embolism, 
etc.), and patients with metastatic cancer or hematologi-
cal malignancy with a poor short-term prognosis and/or 
with an end-of-life decision.
Data collection The present study is a retrospective 
analysis of a database with prospective collection of the 
following data:
Baseline characteristics
  • Characteristics related to COPD: time course, forced 
expiratory volume in one second (FEV1) base (when 
available), regular treatments (short- or long-acting 
β2 agonists, inhaled or systemic corticosteroids, ami-
nophylline, etc.), and home oxygen therapy.
  • Comorbidities: diabetes, hypertension, and heart fail-
ure.
Characteristics of the episode of exacerbation
  • Simplified Acute Physiology Score (SAPS) II [39].
  • Initial arterial blood gas analysis.
Management
  • First ventilation method used at ICU admission: con-
ventional ventilation or NIV.
  • Initial empiric antibiotic therapy or not: empiric anti-
biotic therapy was prescribed at the discretion of 
the physician in charge throughout the study period 
without relying on infection biomarkers such as pro-
calcitonin or CRP.
  • Other treatments used during AECOPD which was 
also at the physician in charge’s discretion: inhaled β2 
agonists and systemic corticosteroids.
  • NIV failure
  • Total duration of mechanical ventilation.
Outcomes
  • Occurrence of complications such as ventilator-asso-
ciated pneumonia (VAP) and the day of onset.
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  • ICU mortality.
  • Transfer to another ward or discharge home.
  • For survivors at the end of ICU stay: the last arterial 
blood gas analysis before ICU discharge (when avail-
able).
Definitions
  • COPD, COPD exacerbation, and respiratory failure 
were defined according to the global initiative for 
chronic obstructive lung disease (GOLD) [4].
 – COPD is defined as a chronic disease whose pulmo-
nary component is characterized by airflow limita-
tion that is not fully reversible. Airflow limitation 
was deemed to be present if the post-bronchodilator 
ratio of forced expiratory volume in 1 s (FEV1)/forced 
vital capacity (FVC) ratio was <0.7. Patients with sus-
pected COPD and without previous documentation 
of the FEV1/FVC ratio had pulmonary function tests 
routinely checked on discharge from the ICU.
  – COPD exacerbation corresponds to a change in 
patient’s baseline dyspnea, cough, and/or sputum 
requiring a change in regular medication.
  – Severe exacerbation requiring ICU admission was 
defined by an actual or impending acute respira-
tory failure, with severe hypoxemia (arterial oxy-
gen tension, PaO2  <60  mmHg and/or arterial 
oxygen saturation  <90  % on room air) associated 
with hypercapnia (arterial carbon dioxide tension 
(PaCO2)  ≥45  mmHg and pH  ≤7.35) and clinical 
signs of excessive respiratory muscle activity (con-
traction of accessory respiratory muscles and respi-
ration rate ≥25 breaths min−1), and/or other organ 
dysfunction (shock or hemodynamic instability, 
neurological disorders).
  • Initial ventilation method used at ICU admission was 
preferably non-invasive ventilation (NIV) in non-
already intubated patients who were free from hemo-
dynamic instability or neurological disorders.
  • NIV failure was defined either by secondary intuba-
tion regardless of the initial NIV duration, or death 
during NIV. Patients were usually considered to need 
tracheal intubation if any of the following major cri-
teria were present: hypercapnia with respiratory aci-
dosis (pH  ≤7.20 and below its value at inclusion); 
hypercapnic coma (Glasgow Coma Scale  ≤8 and 
PaCO2  ≥60  mmHg); PaO2  <45  mmHg despite a 
maximum tolerated inspiratory oxygen fraction; and/
or cardiac arrest.
  • Initial empiric antibiotic therapy corresponds to that 
administered during the first 24 h of ICU admission 
for the treatment of the cause of exacerbation.
  • VAP in intubated patients was diagnosed on the 
basis of the association of clinical criteria and 
quantitative culture of tracheal aspirate. In non-
intubated patients, sputum culture was performed 
and the quality of sampling checked (quality crite-
ria were:  >25 neutrophils and  <5 epithelial cells per 
field). VAP density was calculated for patients either 
under conventional or non-invasive ventilation 
(expressed in 1000 patient-days of ventilation).
Statistical analysis
Data were expressed as median (25–75 percentiles 
interquartile ranges, IQR) and compared with the 
Mann–Whitney test for continuous variables; dichoto-
mous variables were expressed with percentages and 
compared with the Chi-square test. Patients’ charac-
teristics (age, gender, comorbidities, mortality, etc.) 
were analyzed from the index hospital admission (last 
dated admission), while the variables related to epi-
sodes (severity scores, pH, ventilatory modalities, 
empiric antibiotic therapy, VAP rate, VAP density, 
etc.) were analyzed for all hospitalization episodes. 
The analysis of trends over years was performed using 
Chi-square test for trend for categorical variables and 
Spearman’s correlation coefficient test for continuous 
variables.
Univariate and multivariate regression (including vari-
ables with p value <0.2) analyses were performed to iden-
tify risk factors associated with mortality (440 patients 
were analyzed, and for patients admitted several times 
the last episode was considered).
A value of p  < 0.05 was considered to be statistically 
significant. SPSS (version 17; SPSS, Chicago, IL, USA) 
was used for statistical analyses.
Results
During the study period, 961 out of 4425 patients admit-
ted to the ICU had acute on chronic respiratory failure; 
409 did not fulfill the definition of COPD exacerba-
tion (principally because of an obvious reversible cause) 
were not included in the analysis. Of the remaining 
patients with AECOPD, 440 were admitted 552 times 
(89 were hospitalized two or more times for AECOPD) 
and were included in the analysis (Fig. 1). Two-thirds of 
patients were admitted from the emergency department. 
Table 1 shows the baseline characteristics of the included 
patients, and Table  2 reports the variables related to 
COPD exacerbation episodes.
Most patients (84.5 %) were male; their median age was 
68 years (IQR 61–74) and median SAPS II score 27 (IQR 
21–34). The median time course of COPD was 7  years 
(IQR 4–15) and the median forced expiratory volume in 
1 s (FEV1) was 965 ml (IQR 700–1060).
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Changes in clinical characteristics, management, 
and outcomes during the study period
Table  3 summarizes the changes over the study period 
of the following variables: age, initial clinical severity 
(reflected by SAPS II score and pH at admission), the 
frequency of NIV use as the primary ventilation method 
and that of empiric antibiotic administration, the rate of 
VAP occurrence, and the ICU mortality rate.
The median age of patients did not change over the 
study period. However, there was a statistically signifi-
cant increase in arterial pH at ICU admission (median 
pH varied from 7.23 in 2000 to 7.30 in 2012, p < 0.001). 
There was also a slight, but statistically significant trend 
toward a decrease in SAPSII score over the study period 
(p = 0.018).
The use of non-invasive ventilation as the primary 
ventilation method increased substantially from 29 % in 
2000 to 96.7 % in 2012 (p < 0.001), and the NIV failure 
rate went down from around 30 % in the early 2000s to 
10 % by the end of the study period (p = 0.004) (Table 3; 
Fig. 2). Meanwhile, empiric antibiotic administration was 
less common at the end of the study period (p < 0.001) 
(Table 3; Fig. 2). The most frequently administered anti-
biotics were cotrimoxazole (48  %), fluoroquinolones 
(37  %), amoxicillin–clavulanic acid (7  %), and a combi-
nation of third-generation cephalosporin and fluoroqui-
nolone (5 %).
VAP density significantly decreased during the study 
period (22.98 in 2000 to 10.27 for 1000 patient-day of 
ventilation in 2012; p  =  0.002), with a trend toward a 
4425 ICU admissions  
961 admissions in COPD 
paents for acute 
respiratory failure 
552 episodes of 
AECOPD/440 paents 
409 exclusions: 
- 135 pneumonia; 
- 159 CPE; 
- 22 pneumothorax ; 
- 14 malignancies 
- 79 missing data 
Invasive venlaon at 
ICU admission  
178 (32.2%)




therapy    
205 (54.8 %) 
No Empiric 
anbioc 
therapy        
169 (45.2 %) 
Empiric 
anbioc 
therapy        
120 (67.4 %) 
No Empiric 
anbioc 
therapy        
58 (32.6 %) 
Overall Empiric 
anbioc therapy 
  325 (58.9%) 
Fig. 1 Study flowchart
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reduced mortality rate despite wide annual variations 
(12.9 % in 2000 and 6.7 % in 2012, p = 0.058) (Table 3), 
an overall ICU mortality at 15.7  % (69 deaths), and a 
standardized mortality ratio (SMR) of 1.9 according to 
the SAPS II score.
Empiric antibiotic therapy and outcomes
Overall, empiric antibiotic therapy was administrated 
in 325 out of 552 AECOPD (58.9  %). The multivariate 
analysis showed that the empiric antibiotic therapy had 
no impact on the ICU mortality rate which occurred in 
15.3 % of patients who received empiric antibiotics ver-
sus 16.1  % in those who did not (Chi square p =  0.895 
and 0.793 by log rank for the Kaplan–Meier analysis; 
Fig. 3). Conversely, VAP was diagnosed more frequently 
in the group of patients who did not receive antibiotics at 
admission (16.3 %) than in those who received antibiot-
ics (8 %, Chi square p = 0.004, <0.0001 by log rank test 
analysis) (Fig. 3).
NIV and outcomes
At ICU admission, 374 patients (67.8  %) were started 
with NIV as the primary ventilation method, and 178 
(32.2 %) were invasively ventilated. Both VAP and ICU 
mortality rates were significantly higher in patients 
who received invasive ventilation compared to those 
who were initially non-invasively ventilated with, 
respectively, 23.6 versus 5.6 % for VAP rate (Chi square 
p < 0.001; log rank test, p < 0.001) and 31.8 versus 7 % 
for ICU mortality (Chi square p < 0.001; log rank test, 
p < 0.001) (Fig. 4).
NIV failure and outcomes
Overall, NIV as the primary ventilation method failed in 
63 out of the 374 patients (16.8 %). NIV failure was asso-
ciated with a significant increase in the VAP rate com-
pared to non-failing NIV (20.6 versus 2.6 %, respectively, 
Chi square p < 0.001, log rank test, p < 0.001), and that of 
ICU mortality (41 versus 1.6 %, respectively, Chi square 
p  <  0.001, log rank test, p  <  0.001). Patients who even-
tually failed primary NIV had rates of VAP and mortal-
ity similar to those who received invasive ventilation as 
the primary ventilation method: 20.6 versus 23.6 %, and 
41 versus 32 % for VAP and ICU mortality, respectively 
(Fig. 4).
Factors associated with outcomes
Univariate analysis disclosed age, cardiovascular comor-
bidities, SAPS II score, pH at admission, NIV use as 
a first-line ventilation method, NIV failure, and VAP 
occurrence as variables associated with ICU mortal-
ity (Table 4). Multivariate logistic regression disclosed a 
unique protective variable against fatal outcome: the use 
of NIV as the primary ventilation method (odds ratio, 
OR = 0.08; 95 % confidence interval 0.03–0.22; p < 0.001). 
NIV failure, VAP occurrence, and cardiovascular 
Table 1 Baseline characteristics of the study patients
FEV1 forced expiratory volume in 1 s, COPD chronic obstructive pulmonary 
disease, med median, IQR inter-quartile range, M male, F female
Variables All patients: n = 440
Age (n = 440) med (IQR) 68 (61–74)
Gender (M/F) 372/68
FEV1 (ml) (n = 92) med (IQR) 965 (700–1060)
Time course of COPD (years) (n = 243) med (IQR) 7 (4–15)
Comorbidities
 Diabetes n (%) 81 (18.4)
 Hypertension n (%) 127 (28.9)
 Cardiac failure n (%) 36 (8.2)
Oxygen home therapy n (%) 93 (21.1)
Baseline treatment
 Aminophylline n (%) 107 (24.3)
 Short‑action duration ß2 mimetics n (%) 197 (44.7)
 Long‑action duration ß2 mimetics n (%) 46 (10.4)
 Anticholinergics n (%) 39 (8.9)
 Inhaled corticosteroids n (%) 116 (26.4)
 Systemic corticosteroids n (%) 37 (8.4)
Table 2 Variables related to COPD exacerbation
SAPS Simplified Acute Physiology Score, ICU intensive care unit, PaO2 arterial 
oxygen tension, PaCO2 arterial carbon dioxide tension, HCO3
− bicarbonate 
concentration, CRP C reactive protein, WBC white blood cells, NIV non-invasive 
ventilation, VAP ventilator associated pneumonia, med median, IQR inter-
quartile range
Variables All hospitalisations: n = 552
SAPS II (n = 533) med (IQR) 27 (21–34)
pH at ICU admission (n = 534) med (IQR) 7.28 (7.23–7.32)
PaO2 (mmHg) (n = 534)med (IQR) 66.9 (51–90)
PaCO2 (mmHg) (n = 534) med (IQR) 65.9 (55.6–76.4)
HCO3
− (mmol/l) (n = 534) med (IQR) 31 (27.1–34.8)
CRP (mg/L) (n = 223) med (IQR) 41 (11.3–96.3)
WBC count (cells/µl) (n = 338) med (IQR) 10,800 (8000–14,200)
Modality of ventilation at ICU admission
 Invasive ventilation n (%) 178 (32.2)
 NIV n (%) 374 (67.8)
NIV failure n (%) 63 (16.8)
Empiric antibiotic therapy at ICU admis‑
sion n (%)
325 (58.9 %)
Bronchodilators n (%) 483 (87.5)
Systemic corticosteroids for exacerba‑
tion n (%)
199 (36.1)
VAP n (%) 63 (11.4)
Duration of ICU stay (days) (n = 552) 
med (IQR)
9 (6–14)
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comorbidities increased ICU mortality with respective 
ORs of 17.6 (95 % CI 5.29–58.93; p < 0.001), 11.5 (95 % 
CI 5.17–25.45; p  <  0.001), and 3 (95  % CI 1.37–6.63; 
p = 0.006) (Table 5).
Discussion
Along this 13-year study, there was a sustained increase 
in NIV use and mastering of the intervention as reflected 
by a progressive decrease in the rate of failing NIV 
Fig. 2 Evolution of NIV, NIV failure, and empiric antibiotic therapy use
Fig. 3 Impact of empiric antibiotic therapy on VAP and ICU mortality: analysis with Kaplan–Meier survival method shows that empiric antibiotic 
therapy was associated with a decrease in VAP occurrence (b) (log rank test, p < 0.001), but had no effect on mortality (a) (log rank test, p = 0.793)
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episodes in patients admitted for hypercapnic COPD 
exacerbation. Together with a lower use of tracheal intu-
bation and conventional mechanical ventilation, there 
was a significant decrease in the rate of ventilator-associ-
ated pneumonia and a trend toward a lower ICU mortal-
ity. Changes in the ventilatory management pattern were 
also associated with a reduction in the systematic admin-
istration of empiric antibiotic therapy at admission which 
was more than halved between 2000 and 2012. ICU mor-
tality was significantly impacted by three independent 
variables closely related to patients’ management (NIV 
use, NIV failure rate, and VAP density) and only one non-
modifiable factor which was related to the patient’s previ-
ous clinical status (cardiovascular comorbidities).
The abrupt drop of empiric antibiotic therapy by the 
year 2007 is not related to a change in antibiotic policy. 
Until then, empiric antibiotic therapy was generously 
prescribed by physicians in charge according to evidence 
generated in their own ICU [33] and to recommenda-
tions [4], However, the sustained decrease in the VAP 
density and more generally that of the infectious burden 
(which paralleled the increase in NIV use) seems to have 
had an impact on antibiotic-prescribing patterns which 
relied less frequently on the almost systematic adminis-
tration of empiric antibiotic therapy. The impact of the 
new ventilation modalities on patterns of antibiotic pre-
scription seems to have been only postponed in compari-
son to the time course of the infectious risk.
The observational design of our study may have not suf-
ficiently controlled for confounding factors impacting the 
choice of ventilation mode or the decision of antibiotic 
prescribing. However, the fact that the same physicians 
took these decisions throughout the study period has 
probably contributed to lessening the risk of selection 
bias. Notwithstanding, in the present study, the choice of a 
hard outcome such as ICU mortality precludes from other 
threats to observational studies such as detection bias.
Recent surveys show that NIV use has increased world-
wide to become the mainstay for hypercapnic COPD exac-
erbation requiring ventilatory support [35, 40–43]. Several 
controlled studies have indeed provided compelling evi-
dence on the effectiveness of NIV in hypercapnic exacer-
bation of COPD [44–47]. NIV is indeed associated with a 
substantial decrease in the use of intubation and invasive 
ventilation, the frequency of complications and adverse 
events, lengths of ICU and hospital stay, and mortality 
rates [48]. In keeping with our observation, Girou et  al. 
[37] reported that the increase in NIV use in ICU patients 
admitted for COPD exacerbation (from 45  % to almost 
90 % between 1994 and 2001) was associated with a lower 
Fig. 4 Impact of ventilation method at ICU admission and that of NIV failure on VAP rate and ICU mortality: analysis with Kaplan–Meier method 
shows that NIV was significantly associated with a decrease in VAP (b) and ICU mortality rates (a), (log rank test, p < 0.001). Conversely, NIV failure 
was associated with higher rates of VAP and death in the ICU compared with patients ventilated with NIV only (log rank test, p < 0.001) and similarly 
to primary invasive mechanical ventilation
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incidence of nosocomial infections overall and specifically 
that of VAP [38]. NIV was also an independent factor of 
mortality reduction. The current study confirms previous 
findings on the association of NIV with a positive clini-
cal outcome in several respects (VAP, length of stay) and 
extends the scope of benefits to a more sparing use of anti-
biotics (with potential reduction of the selection pressure 
and emergence of multidrug-resistant bacteria).
Despite the widespread use of antibiotics in COPD 
exacerbation, evidence supporting their use stems from 
small-sized studies [29, 49, 50]. In addition, the expected 
effect of antibiotics on mortality reported in meta-analy-
ses is heavily impacted by our previous study [33] show-
ing a substantial reduction in mortality among COPD 
patients with exacerbation treated with antibiotics [14, 
51–53]. Furthermore, the most recent meta-analysis pro-
vided inconsistent results regarding inpatients (COPD 
with severe exacerbations) and outpatients with mild to 
moderate exacerbations [51].
The current study confirms our previous findings on the 
benefit of empiric antibiotic therapy regarding end points 
such as a shorter duration of mechanical ventilation and 
the length of hospital stay [33]. However, although both 
studies dealt with the same type of patients, cared for 
in a tertiary ICU by essentially the same doctors, with a 
similar clinical approach, the current study does not con-
firm the beneficial effect of empiric antibiotic therapy on 
mortality. Both reports differ in fact in one major aspect: 
the method of ventilation. In the study by Nouira et  al. 
[33], no less than 84  % patients were eventually venti-
lated with conventional invasive ventilation (31 % as the 
primary ventilation method, and the remaining were sec-
ondarily intubated following NIV failure). The propor-
tion of patients ventilated invasively is currently as low as 
5–10  % with a lower failure rate (around 10  %) in rela-
tion with a better mastery of NIV, the so-called learning 
curve, as underscored by Dres et al. [54]. The use of NIV 
and its success appear to impact heavily patients’ out-
come. As a matter of fact, our current study and the one 
that proceeded should not be regarded as inconsistent, 
Table 4 Univariate analysis and variables associated with ICU mortality
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, SAPS Simplified Acute Physiology Score, NIV non-invasive ventilation, VAP ventilator 
associated pneumonia, med median, IQR inter-quartile range
Variables with p value < 0.2 are presented in italic
Variables Survivors (n = 372) Dead (n = 68) p
Age med (IQR) 68 (60–73) 70 (62–76) 0.031
Gender (M/F) 313/58 59/10 1.000
Time course of COPD (years) med (IQR) 7 (4–15) 8.5 (3.5–15) 0.506
FEV1 (ml) med (IQR) 860 (700–1070) 900 (775–1030) 0.489
Diabetes n (%) 69 (18.6) 12 (17.4) 1.000
Cardiovascular comorbidities n (%) 107 (28.8) 27 (39.1) 0.116
Oxygen home therapy n (%) 77 (34) 16 (29.3) 0.495
SAPS II med (IQR) 27 (21–34) 32 (26–37) 0.003
pH at admission med (IQR) 7.29 (7.24–7.33) 7.25 (7.19–7.30) 0.001
NIV at admission n (%) 266 (71.7) 20 (29) <0.001
Invasive ventilation at admission n (%) 105 (28.3) 49 (71) <0.001
NIV failure n (%) 24 (9) 16 (80) <0.001
Empiric antibiotic therapy at ICU admission n (%) 210 (56.6) 38 (55.1) 0.895
Bronchodilators n (%) 204 (79.7) 37 (78.7) 0.846
Systemic corticosteroids n (%) 121 (33.2) 30 (44.1) 0.097
VAP n (%) 23 (6.1) 38 (55.1) <0.001
Table 5 Multivariate analysis: independent factors associ-
ated with ICU mortality
SAPS Simplified Acute Physiology Score, VAP ventilator-associated pneumonia, 
NIV non-invasive ventilation, OR odds ratio, CI confidence interval
OR CI 95 % p
Min Max
Age (per year) 0.967 0.933 1.002 0.062
SAPSII (per point) 1.017 0.981 1.054 0.371
Cardiovascular comorbidities 3.022 1.377 6.631 0.006
pH admission (per 0.01 decrease) 1.024 0.986 1.064 0.211
VAP 11.471 5.170 25.452 <0.001
NIV at admission 0.079 0.028 0.221 <0.001
NIV failure 17.663 5.294 58.932 <0.001
Systemic corticosteroids 1.543 0.752 3.166 0.237
Empiric antibiotic therapy at  
ICU admission
1.281 0.607 2.704 0.515
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and the results reported herein actually reinforce our ear-
lier hypothesis, attributing the benefits of routine empiric 
antibiotic therapy to a preventive effect on the occur-
rence of VAP. The higher rate of intubated patients in the 
study by Nouira et  al. [33] means also a greater risk of 
developing VAP compared to current patients, whereas 
using NIV translates into a decreased risk of VAP, which 
was disclosed as an independent risk factor for mortal-
ity in the current study. This assertion seems reinforced 
by our findings of similar outcomes (VAP and mortality 
rates) in patients who failed NIV and in those managed 
with conventional ventilation only. These patients behave 
worse than those with successful NIV.
Taken together, our previous publication and the cur-
rent report strongly suggest that routine administration 
of antibiotics is probably legitimate in case of high risk 
of VAP (i.e., with conventional ventilation), whereas it is 
less justified when most COPD patients with exacerba-
tion requiring ventilator support are managed using non-
invasive ventilation, which portends a lower risk of VAP.
Conclusion
This study shows that the increasing use of NIV in COPD 
exacerbation requiring ventilatory support over the last 
13  years was associated with lower rates of NIV fail-
ure, VAP, and a trend toward a reduced mortality in the 
ICU. Changes in the first-line ventilation methods were 
associated with a substantial reduction in empiric anti-
biotic therapy prescribing. Moreover, ICU mortality was 
impacted by one non-modifiable factor (cardiovascular 
comorbidities) and three variables related to patterns of 
ventilatory management: the rate of NIV use as a first-
line ventilation method, the rate of NIV failure, and the 
rate of VAP, whereas empiric antibiotic therapy had no 
impact on patients’ outcome.
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